IMVT241115P31000
- 0.00
- 0.000.00%
Immunovant Newsroom
Argenx Upgraded at Wolfe on Myasthenia Gravis Dominance
Immunovant's Strategic Advances in Autoimmune Therapies
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $48 to $58
Immunovant's Promising Pipeline and Strategic Advancements Justify Buy Rating
Immunovant Price Target Raised to $58 From $52 at Stifel
Immunovant Reports Q3 EPS (74c), Consensus (60c)
Immunovant | 10-Q: Q2 2025 Earnings Report
Express News | Immunovant: As of Sept 30, 2024, Immunovant's Cash and Cash Equivalents Totaled About $472.9 Mln
Earnings Flash (IMVT) IMMUNOVANT Reports Q3 Loss $-0.74 Per Share
Immunovant 2Q Research and Development Expenses $97.3M >IMVT
Express News | Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Press Release: Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024
Express News | Immunovant Q2 Net Income USD -109.119 Million
Express News | Immunovant Q2 Basic EPS USD -0.74
Promising Phase 2a Results for Immunovant's Batoclimab Support Buy Rating
Press Release: HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting
Express News | Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves’ Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting